Introduction Treatment protocols for hepatocellular carcinoma (HCC) are evolving rapidly. We sought to determine long-term outcomes in patients with HCC treated with DEB-TACE as stand alone or part of multimodality treatment at a single centre. Methods Our departmental database of HCC, diagnosed using EASL radiological criteria, was reviewed retrospectively. From August 2006 to January 2011, 80 patients (60 males/20 females) underwent DEB-TACE some of which also had surgery and/or percutaneous ablation. A total of 186 episodes of DEB-TACE treatment were performed (minimum 1 episode and maximum 8 episodes per patient). 37.5% of patients presented with multifocal disease, a further 7.5% presented with tumour plus satellites. The mean MELD (model for end-stage liver disease) in this cohort was 9.53 (range 6e22). Demographics, procedural details, clinical measures and outcomes were studied. Median age was 69 years (range 33e87). All patients were included in the survival analysis. Overall survival was described using KaplaneMeier methods.Results 53 patients with a median tumour size of 49 mm (range 12e163 mm) were treated with DEB-TACE alone with a mean number of procedures of 2.1. Here median survival was 28.5 months (798 days). The 1-and 3-year survival rates in this group where 66% and 38% respectively. 27 patients (median tumour size of 40 mm (range 12e100 mm)) were treated with a combination of therapies and at 55 months (1540 days) the median survival had not been reached. Survival in this group was 51.1% at time data collection. In this group the 1-and 3-year survival rates were 86% and 64% respectively. In our cohort of patients DEB-TACE both with or without combination therapies, resulted in median survival of 44 months. Overall survival rates at 1-and 3-years were 74.5% and 50.3% respectively. There were no deaths at 30 days following a DEB-TACE episode. Conclusion In our centre this procedure is safe and well tolerated with multimodality treatment showing an improved survival outcome. Our results highlight the importance of a multidisciplinary approach with the application of multimodal therapy in the management of HCC with an improved survival for appropriately selected patients. Introduction Acoustic Radiation Force Impulse (ARFI, Virtual Touch Ó ) elastography is a novel validated technique for measuring liver stiffness (LS), with advantages over transient elastography including greater accuracy in ascites or obesity. However, elastography has not been well studied in acutely ill patients with decompensated chronic liver disease (CLD). We report our experience in a consecutive controlled cohort in a secondary care setting. Aims: (1) To establish whether LS is significantly different in patients hospitalised for decompensated CLD from outpatient controls with proven cirrhosis; (2) To investigate correlation between ARFI and severity scores such as DF, GAH, Lille, Child Pugh and MELD. Methods ARFI was performed by a single radiologist, using a standard 10 observation technique. 108 patients were studied:...
Introduction Treatment protocols for hepatocellular carcinoma (HCC) are evolving rapidly. We sought to determine long-term outcomes in patients with HCC treated with DEB-TACE as stand alone or part of multimodality treatment at a single centre. Methods Our departmental database of HCC, diagnosed using EASL radiological criteria, was reviewed retrospectively. From August 2006 to January 2011, 80 patients (60 males/20 females) underwent DEB-TACE some of which also had surgery and/or percutaneous ablation. A total of 186 episodes of DEB-TACE treatment were performed (minimum 1 episode and maximum 8 episodes per patient). 37.5% of patients presented with multifocal disease, a further 7.5% presented with tumour plus satellites. The mean MELD (model for end-stage liver disease) in this cohort was 9.53 (range 6e22). Demographics, procedural details, clinical measures and outcomes were studied. Median age was 69 years (range 33e87). All patients were included in the survival analysis. Overall survival was described using KaplaneMeier methods.Results 53 patients with a median tumour size of 49 mm (range 12e163 mm) were treated with DEB-TACE alone with a mean number of procedures of 2.1. Here median survival was 28.5 months (798 days). The 1-and 3-year survival rates in this group where 66% and 38% respectively. 27 patients (median tumour size of 40 mm (range 12e100 mm)) were treated with a combination of therapies and at 55 months (1540 days) the median survival had not been reached. Survival in this group was 51.1% at time data collection. In this group the 1-and 3-year survival rates were 86% and 64% respectively. In our cohort of patients DEB-TACE both with or without combination therapies, resulted in median survival of 44 months. Overall survival rates at 1-and 3-years were 74.5% and 50.3% respectively. There were no deaths at 30 days following a DEB-TACE episode. Conclusion In our centre this procedure is safe and well tolerated with multimodality treatment showing an improved survival outcome. Our results highlight the importance of a multidisciplinary approach with the application of multimodal therapy in the management of HCC with an improved survival for appropriately selected patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.